Avid Bioservices Inc (CDMO)

[4OurRetirement]

CJ, It Looks Like Embargoed Info Is Available...

per the link you supplied, it no longer says "embargoed" and the following info has been published:
***********************************************************************************
Session PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress
CT159 / 25 - IFN-? analysis in blood and tissue as a potential prognostic and/or predictive biomarker
Add To My Itinerary
April 3, 2017, 1:00 - 5:00 PM Section 33
Presenter/Authors
Nikoletta Kallinteris1, Leora Horn2, Min Tang1, Tobias Guennel3, Shen Yin1, Jennifer Lai1, Joseph Shan1, Rachel E. Sanborn4. 1Peregrine Pharmaceuticals, Inc., Tustin, CA; 2Vanderbilt-Ingram Cancer Center, Nashville, TN; 3Precision for Medicine, Frederick, MD; 4Providence Cancer Center, Portland, OR
Disclosures
N. Kallinteris: ; Peregrine Pharmaceuticals Inc. L. Horn: ; Abbvie. ; BMS. ; Merck. ; Eli Lilly. ; Genentech. ; Xcovery. ; Boehringer Ingelheim. M. Tang: ; Peregrine Pharmaceuticals Inc. T. Guennel: ; Precision for Medicine. S. Yin: ; Peregrine Pharmaceuticals, Inc. J. Lai: ; Peregrine Pharmaceuticals, Inc. J. Shan: ; Peregrine Pharmaceuticals, Inc. R.E. Sanborn: ; AMGEN. ; Seattle Genetics. ; Peregrine Pharmaceuticals Inc.. ; Ariad. ; AstraZenecca. ; Research funding; Bristol-Myers Squibb. ; Research funding; MedImmune. ; Research funding; Merck.
Abstract
Background
SUNRISE, a global, double-bind, Phase III trial of docetaxel (D) plus bavituximab (B) or D plus placebo (P) in previously treated non-squamous non-small cell lung cancer (NSCLC), demonstrated similar overall survival (OS) in both treatment arms. Immune correlate analyses including pre-treatment IFN-? levels in blood and tumor tissue were used to potentially identify prognostic and/or predictive correlation with clinical outcome.
Methods
Serum was isolated from all randomized NSCLC patients at screening, periodically during treatment and at disease progression for evaluation of IFN-? levels using the SimoaTM assay (Myriad RBM, Austin, TX, USA). Available archival tissue was also tested for 91- immune gene activation markers, including IFN-? by the Fluidigm-based gene-expression platform (Sirona Dx, Lake Oswego, OR, USA). Kaplan-Meier statistical methods and Cox proportion hazards models were utilized to evaluate and contrast the correlation of peripheral and intratumoral IFN-? levels with OS. Patients were classified paradoxically as IFN-? "low" with a favorable disease prognosis versus "high" associated with more aggressive disease based on the median.
Results
Pretreatment serum results were available for 582 out of the 597 randomized patients. Each patient was classified to be pre-treatment IFN-? high or low (< cut-off) using cut-off 0.093 pg/ml, which is the median IFN-? value in the D+B group. Median overall survival (mOS) in all patients with IFN-? low is 11.3 months (95% confidence interval [CI], 10.1-13.5) versus 10.4 months (95% CI, 8.4-11.3) in all IFN-? high; p=0.047. mOS of D+B arm is 11.6 months (95% CI, 10.2-13.9) and 11.1 months (95% CI, 9.1-14.7) in the D group; p=0.982 for IFN-? low. mOS of D+B arm is 9.0 months (95% CI, 6.7-11.2) and 10.6 months (95% CI, 8.9-13.0) in the D group; p=0.252 for IFN-? high. With the limited intratumoral IFN-? gene expression data (n=33), no statistically significant correlation with OS was observed.
Conclusions
Correlative approaches identified low peripheral low IFN-? at pretreatment as a biomarker of interest correlating with more favorable clinical outcomes and is consistent with the hypothesis that bavituximab may demonstrate more immunomodulatory effects in patients with “immune cold” tumors.

http://www.abstractsonline.com/pp8/#!/4292/presentation/12566

Glta StockHOLDERS!